

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

DAERON, et al.

Atty. Ref.: 1721-66

Serial No.: Cont. of Serial No. 09/331,885

Group: Unassigned

Filed: July 10, 2003

Examiner: Unassigned

For: COMPOUNDS FOR MODULATING CELL NEGATIVE
REGULATIONS AND BIOLOGICAL APPLICATIONS
THEREOF

* * * * *

Assistant Commissioner for Patents
Washington, DC 20231

July 10, 2003

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449, copies of each identified
document has been submitted and made of record in the parent

application Serial No. 09/331,885. Further copies of the cited documents are not believed to be required however the office is requested to advise the undersigned if otherwise.


This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
 - ☐ a) The required Statement made in item 8 below; or
 - ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and and Rule 17(p) fee), but before final fee payment]; and
 - ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
 - ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
 - ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
 - ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

DAERON, et al.
Cont. of Serial No. 09/331,885

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: _____


B. J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

1721-66

Cont. of Serial No. 09/331,885

APPLICANT

DAERON, et al.

(Use several sheets if necessary)

FILING DATE

GROUP

July 10, 2003

Unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,731,168	03/1998	CARTER et al.			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
WO 96 26961 A	9/06/1996	WIPO				
WO 92 17198 A	10/15/199	WIPO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	H. KATZ ET AL.: "Mouse mast cell gp49B1 contains two immunoreceptor tyrosine-based inhibition motifs and suppress mast cell activation when coligated with the high-affinity Fc receptor for IgE." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 93, no. 20, 1 October 1996, WASHINGTON, DC, USA, pages 10809-10814, XP000676589.
	S. SIVORI ET AL.: "CD94 functions as a natural killer cell inhibitory receptor for different HLA class I alleles: identification of the inhibitory form of CD94 by the use of novel monoclonal antibodies.: EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 26, no. 10, October 1996, WEINHEIM, GERMANY, pages 2487-2492, XP000676591.
	M. BLÉRY ET AL.: "Reconstituted killer cell inhibitory receptors for major histocompatibility complex class I molecules control mast cell activation induced via immunoreceptor tyrosine-based activation motifs." THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 14, 4 April 1997, BALTIMORE, MD. Pages 8989-8996, XP002033956.
	J. CAMBIER: "Inhibitory receptors abound?" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 94, no. 12, 10 June 1997, WASHINGTON, DC, USA, pages 5993-5995, XP002061987.
	VÉLY et al., "Function of Killer Cell Inhibitory Receptors for MHC Class I Molecules", Immunology Letters 54 (1996) pp. 145-150
	OLCESE et al., "Human and Mouse Killer-Cell Inhibitory Receptors Recruit PTP1C and PTP1D Protein Tyrosine Phosphatases", Journal of Immunology, 156 (1996) pp 4531-4534
	BEERS et al., The Merck Manual of Diagnosis and Therapy, 17 th Edition, 1999, Merck Research Laboratories, Whitehouse Station, N.J., pages 973-979
	WISCHMEYER et al., Receptor stimulation causes slow inhibition of IRK1 inwardly rectifying K ⁺ channels by direct protein kinase A- mediated phosphorylation. Proc. Natl. Acad. Sci. USA. 1996, Vol. 93, 5819-5823
	BURSHTYN et al., Recruitment of Tyrosine Phosphatase HCP by the Killer Cell Inhibitory Receptor, Immunity, 1996, Vol. 4, pages 77-85

*Examiner		Date Considered	
-----------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)